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Abstract
The coronavirus disease 2019 (COVID-19) is a master killer which appeared suddenly and which has already claimed 
more than 200,000 human lives. In this situation, laboratories are in urgent need for a COVID-19 murine model to 
search for effective antiviral compounds. Here we propose a novel strategy for the development of mice that can be 
inoculated by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the COVID-19 causative agent. In 
humans, two proteins – ACE2 and TMPRSS2 – are involved in SARS-CoV-2 cells entry and, thus, we decided to intro-
duce their genes into a murine genome. These genes will be placed with LoxP sites under the murine Tmprss2 promoter. 
Such an approach can provide a representative model with the opportunity to control the viral sensitivity of an animal 
population and tissue specificity of hACE2 and hTMPRSS2 expression.
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The new COVID-19 model should be based on inducible co-expression of the human ACE2 and TMPRSS2 genes. Acti-
vation of ACE2 and TMPRSS2 genes will occur only in the virological laboratory, after crossbreeding with Cre-mice. 
Before activation, mice will be resistant to SARS-CoV-2 for their biological safety during the pandemic.
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Background
The COVID-19 outbreak is a dramatic, rapidly evol-
ving situation. The search for effective approaches to 
SARS-CoV-2 infection therapy and prevention has be-
come one of the most important tasks for medicine now 
and in the foreseeable future. Every day, doctors and 
scientists receive more and more information about the 
effectiveness of classic antiviral medications and some 
off-label-used drugs.
However, these data should also be quickly supple-
mented by the results of pre-clinical studies that can 
provide much useful and even crucial information about 
the most effective drugs. Unfortunately, as most labora-
tories do not have an accessible SARS-CoV-2-sensitive 
animal model, this is the main stumbling block for quick 
in vivo screening. The difficulty in obtaining such mod-
els in the pandemic condition directed us to develop our 
own SARS-CoV-2-sensitive mouse model as discussed 
in this paper.
Virus invasion pathway
To enter the target cells, SARS-CoV and SARS-CoV-2 
use their “corona”, which is represented by numerous spi-
ke (S) proteins. It was shown that the S-protein engages 
angiotensin-converting enzyme 2 (ACE2) as the entry re-
ceptor (Li et al. 2003). During viral infection, the trimeric 
S protein is cleaved into S1 and S2 subunits (Belouzard 
et al. 2009; Simmons et al. 2013). Further, the S1 subunit, 
containing the receptor binding domain, directly binds to 
the peptidase domain of angiotensin-converting enzyme 
2 (ACE2) (Li et al. 2005), whereas S2 is responsible for 
membrane fusion.
Although ACE2 is present in many types of tissues 
(Hamming et al. 2004), SARS-CoV is highly pathogenic 
only in the lungs (To and Lo 2004). Furthermore, type 
1 pneumocytes, which poorly express ACE2, are more 
sensitive to viral invasion in comparison with ACE2-
rich type 2 pneumocytes (Matsuyama et al. 2010). The 
selective nature of tissue damage was explained by the 
existence of a second molecule, which also contributes 
to cell contagion. Thus, ACE2 immunoprecipitation 
captured the transmembrane protease/serine subfamily 
member 2 (TMPRSS2), a known human airway and al-
veolar protease (Vaarala et al. 2001). This enzyme was 
shown as one of the up-regulators of coronavirus infec-
tion pathways (Iwata-Yoshikawa et al. 2019). Interac-
tion of ACE2 and TMPRSS2 enhanced the cell entry of 
SARS-CoV and it correlated with TMPRSS2-mediated 
proteolysis of both S and ACE2 proteins (Shulla et al. 
2011). Recently, Hoffmann et al. (2020) have discovered 
that serine protease TMPRSS2 is employed by SARS-
CoV-2 for S protein priming and the TMPRSS2 inhibitor 
prevents virus entry.
Homology between human and 
mouse ACE2 proteins
Human and mouse ACE2 enzymes consist of 805 amino 
acids with 81.86% interspecies homology. Both hACE 
and mACE have Collectrin (75.97%) and Peptidase M2 
(interdomain similarity = 84.62%) domains and the latter 
directly interacts with S-protein. It has only recently been 
identified that amino acids Asp30, His34, Tyr41, Gln42, 
Lys353, Arg357, Gln24 and Met82 of human ACE2 play 
a key role in binding with viral S-protein (Yan et al. 2020). 
Alignment of mouse and human protein ACE2 sequences 
showed that five of these eight residues differ in human 
and mice. The similarity between TMPRSS2 cleavage 
sites (amino acids 697–716) of hACE2 and mACE2 pro-
teins is 78.95% (Fig. 1).
Three regions of SARS-CoV-2 binding site are shown. 
Five of eight key residues differ between mouse and hu-
man aligned sequences (highlighted in red) when three 
amino acids coincide (highlighted in green). In addition, 
alignment of mouse and human ACE2 TMPRSS2 cleav-
age sites is presented below.
Homology between human and 
mouse TMPRSS2 proteins
Both human and mouse TMPRSS2 proteins consist of 4 
domains: Transmembrane; LDL receptor class A; Sca-
venger receptor cysteine‐rich; and Serine protease. Muri-
ne TMPRSS2 protein contains 492 amino acids and sha-
res 81.4% similarity and 77.3% identity with the human 
one. The details of comparison were presented in Vaarala 
et al. (2001).
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Figure 1. Alignment of human and mouse ACE2 protein sequences.
Mouse models of SARS-CoV 
infection
Naturally, mice are low-sensitive to SARS-CoV infecti-
on, but can be poorly inoculated by the virus. To improve 
the virus inoculation, a few transgenic lines of mice were 
created with humanized ACE2 gene. In the first line, the 
hACE2 gene was introduced under the CAG promoter 
with CMV-IE enhancer (Tseng et al. 2007). This modifi-
cation led to a sharp clinical manifestation with an acute 
wasting syndrome and deaths of the mice within 4 to 8 
days after SARS-CoV inoculation. A second line was de-
veloped by introducing the hACE2 gene regulated by the 
human cytokeratin 18 (K18) promoter. After the SARS-
CoV contagion, these mice demonstrated a clinical picture 
of encephalitis and pneumonia, resulting in death after 3–5 
days of the post-inoculation period (McCray et al. 2007).
The transgenic line, created by the Yang et al. (2007), 
has the most natural tissue expression profile of ACE be-
cause hACE gene was introduced under the mouse’s own 
Ace2-promotor. In this line, SARS-CoV replicated more 
efficiently in the lungs of transgenic mice than in those 
of wild-type mice. After the SARS-CoV inoculation, the 
mice had severe pulmonary lesions, including interstitial 
hyperaemia and haemorrhage, monocytic and lymphocyt-
ic infiltration, protein exudation and alveolar epithelial 
cell proliferation and desquamation.
As SARS-CoV and SARS-CoV-2 have a similar man-
ner of cell contagion, it is believed that the already-cre-
ated models are also sensitive to COVID-19. Bao et al. 
(2020) have recently reported that ACE2-humanized 
mice with ACE2 gene under murine Ace2 promoter have 
sensitivity to SARS-CoV-2, but it is lower than that of 
SARS-CoV. However, these models are not widespread in 
laboratories and we have not found any publication where 
ACE2-humanised mice were used for preclinical studies 
of anti-SARS-CoV-2-therapy. Whereas, since a few mod-
els have already been developed, we can take the availa-
ble experience and try to propose our own strategy for the 
genetic edition.
Novel approach to the creation of 
SARS-CoV-2-sensitive mice
As can be seen, there is not only ACE2 involved in 
SARS-CoV-2 invasion. Therefore, first of all, we consi-
der that mice with two humanized ACE2 and TMPRSS2 
genes will be more sensitive to viral invasion. This ap-
proach will not only make ACE2 more accessible for cle-
avage (which is important for a viral entry), but will also 
open up additional possibilities for drugs testing, such as 
inhibitors of TMPRSS2. Moreover, a high expression of 
TMPRSS2 in the epithelial cells makes it reasonable to 
introduce both hACE2 and hTMPRSS2 under the murine 
Tmprss2 promoter. We believe that the co-expression of 
two virus-inviting molecules in the lung epithelium will 
imitate the events that happen in the human body during 
SARS-CoV-2 invasion.
In brief, to create this model, we are going to clone 
hTMPRSS2 and hACE sequences and introduce it into 
the mouse genome with the use of CRISPR/Cas9 tech-
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Figure 2. Construction for the development of Cre-regulated hACE2/hTMPRSS2 mice.
Table 1. Brief description of the existing SARS-CoV-sensitive transgenic mice.
Promoter Clinical pattern and pathomorphology Lethality level References




Acute wasting syndrome. Death within 
4 to 8 days of post-inoculation period as 
result of inflammatory response in the 
brain (more intensive than in the lungs)  
Damaged tissues: lungs, kidneys, 
liver, heart, skeletal muscle, 
spleen, lymphatic nodes, pancreas, 
gastrointestinal smooth muscle and 
ganglia, vascular endothelium, adrenal 
and central nervous system (CNS)
no data 100% (in mice 
with high hACE2 
expression) 0% 
(in mice with low 
hACE2 expression)








Infection of the CNS is a major factor 
contributing to the fatal outcome 
observed in SARS-CoV-infected mice. 
Damaged tissues: Lungs, colon, small 
intestine, kidneys, liver, spleen, heart
no data 100% no data McCray et al. 




Gross pulmonary edema, focal 
haemorrhage, consolidation and 
lung bullae with no significant 
histopathological lesions or viral 
antigens in myocardium, liver, spleen, 
kidney, cerebrum, intestine and testis. 
Damaged tissues: Viral antigens were 
observed in the bronchial epithelial 
cells, alveolar macrophages and 
alveolar epithelia.
Interstitial pneumonia 
with lymphocytes and 
monocytes infiltration. 
Accumulation of 
macrophages in alveolar 
cavities
0% 0% Yang et al. 2007; 
Bao et al. 2020
nology. hTMPRSS2 and hACE2 will be divided by the 
IRES element for their equivalent expression. Addition-
ally, to create an inducible hACE2/hTMPRSS2 expres-
sion, we wish to place LoxP sites in front of the hTM-
PRSS2 sequence (Fig. 2 for the details). In this manner, 
it will allow provoking SARS-CoV-2 sensitivity only 
after breeding with suitable Cre-mice within virological 
laboratories. For example, Cre-ERT2 mice express ta-
moxifen-induced Cre-recombinase in stem cells. Thus, 
it can cut the stop-cassette between LoxP sites during 
ontogenesis, unlocking the gates to hACE and hTM-
PRSS2 transcription.
Construction consists of homology arms, hTMPRSS2 
sequence, IRES element, hACE2 sequence and an effec-
tive terminator of expression in 3’ regions. Homology 
arms have to direct it next to the murine Tmprss2 pro-
moter with use of CRISPR/Cas9. Transgenic mice can 
be crossbred with Cre-ERT2 mice for the excision of 
the stop-cassette between LoxP-sites and activation of 
hACE2 and hTMPRSS2 transcription.
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Discussion
A previously-unknown coronavirus called SARS-CoV-2 
has crossed the species barrier and caused a human infecti-
on outbreak, first in Wuhan and then around the world. The 
rapidly developing epidemic generated interest in mice ex-
pressing the human receptors for SARS-CoV-2 entry for 
further pharmacological screening (Walls et al. 2020).
In the growing avalanche of SARS-CoV-2 pathogene-
sis details, it is very difficult to focus on specific targets. 
For example, recent insight into the CD147 as a novel 
target of SARS-CoV-2 opens up new possibilities for 
explaining the disease (Wang et al. 2020). Nevertheless, 
here we describe our strategy for the development of the 
novel COVID-19 murine model by humanising ACE2 
and TMPRSS2 genes.
We have formulated the basic requirements for the 
COVID-19 animal model. First of all, transgenic animals 
should not be a “laboratory” reservoir of the virus before 
the start of the pharmacological experiments. Although 
the SARS and MERS were successfully inoculated in 
mice, infection did not spread in animals after intranasal 
administration. In the case of a new SARS-CoV-2 virus, it 
is impossible to predict its degree of contagion from mice 
to mice and human population. For the safety of the lab-
oratory staff, we decided to use LoxP-induced expression 
of humanized genes, as described in (Zvartsev et al. 2018; 
Deykin et al. 2019; Silaeva et al. 2020).
As shown, the hTMPRSS2 and hACE2 proteins are 
jointly involved in the pathogenesis of the SARS-CoV-2 
invasion. Moreover, the expression profiles of these en-
zymes in mice and human intersect at lungs, intestine 
and the male reproductive system epithelium (Vaarala et 
al. 2001; Sungnak et al. 2020). Therefore, we consider it 
appropriate to use the mouse Tmprss2 promoter for the 
expression of human hTMPRSS2 and hACE2 genes in 
the transgenic line. A modern approach to modification 
of the mouse genome in this way would be gene editing, 
based on CRISPR/Cas9. On making a gap after the mTm-
prss2 promoter, a matrix containing homology arms, hT-
MPRSS2 sequence, IRES element, hACE2 sequence and 
an effective terminator of expression in 3’ regions will be 
used to bridge the gap.
It is very important not only for the COVID-19 mu-
rine model to be able to be infected by the SARS-CoV-2, 
but also for the infection process to be as human-like as 
possible. The previous models showed effective infection 
only in high viral load conditions. At the same time, in the 
models based on the K18 promoter, systemic damage, neu-
roinflammation and lethargy developed, which is not quite 
representative of the human clinical picture. In the model, 
created by Yung et al. (2007), the SARS-CoV-2 infection 
led to more human-like clinical disorders, but those mice 
had quite a low level of lethality. The advantages and dis-
advantages of the existing ACE2 humanized mice were 
presented in Gretebeck and Subbarao (2015). We think that 
reproduction of hTMPRSS2 and hACE2 crosstalk in mu-
rine epithelium will be much better because it can intensify 
lung contagion with no influence on brain damage.
Activation of expression is possible after crossbreeding 
with mice constitutively or inducibly expressing Cre-re-
combinase (for example, Cre-ERT2 line). We expect these 
mice to be a safe and representative COVID-19 model.
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